A phase 1 multicenter, randomized, double-blind, placebo-controlled trial to evaluate the safety and immunogenicity of an HIV-1 gag DNA vaccine [HIV DNA vaccine] administered alone or with escalating doses of IL-12 DNA or IL-15 DNA molecular adjuvants to HIV-1 positive adults receiving stable HAART [highly active antiretroviral therapy]
Latest Information Update: 03 Nov 2021
At a glance
- Drugs HIV vaccine (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
- Sponsors Wyeth
- 23 Aug 2007 Status change
- 31 May 2007 Status changed from recruiting to discontinued.
- 09 Dec 2005 New trial record.